Clinical trials
Non Small Cell Lung Cancer Metastatic clinical trials
Below are recruiting non small cell lung cancer metastatic clinical trials, each written for real people, not researchers. We’re tracking 772 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05452005RecruitingPhase 1
PET scan with a new tracer for lung cancer brain metastases
This Phase 1 study tests whether a specialized PET scan tracer can “light up” metastatic non-small cell lung cancer in the brain. If you join, you’ll get brain MRI and PET/CT scans and you’ll continue with your planned cancer treatments and follow-up imaging.
Sacramento, CaliforniaAges 18 years+ - NCT05456256RecruitingPhase 2
LP-300 plus chemo for lung cancer in never-smokers
This Phase 2 trial tests LP-300 with carboplatin and pemetrexed to treat advanced lung adenocarcinoma in people who have never smoked. It may help shrink tumors and slow the disease in a specific genetic group of lung cancer.
Beverly Hills, CaliforniaAges 18 years+ - NCT05473156RecruitingPhase 1/Phase 2
Study of AP203 for advanced solid tumors that grew despite treatment
This early-phase study tests AP203 (an investigational treatment) to see if it is safe and to look for signs it can shrink or control certain advanced cancers. The study includes a dose-finding part for many solid tumors, and a second part focused on specific lung and head/neck cancers that previously received PD-1/PD-L1 therapy.
TaipeiAges 18 years+ - NCT05477979Recruiting
Study how stress affects lung cancer treatment outcomes
This study looks at whether psychological stress changes how well lung cancer treatments work and what the outlook is. You may qualify if you’re about to start (or recently started) certain immunotherapy-based treatments, and you can complete stress and well-being questionnaires.
Changsha, HunanAges 18 years+ - NCT05498428RecruitingPhase 2
Amivantamab for advanced lung cancer with EGFR mutations
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
La Jolla, CaliforniaAges 18 years+ - NCT05498064Recruiting
Study of ensartinib for advanced ALK-positive lung cancer
This real-world study looks at how ensartinib works in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has continued or worsened after ALK-targeted therapy. It may help doctors understand how well the treatment works and who benefits most in everyday care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05522660RecruitingPhase 3
Immunotherapy or targeted therapy with focused brain radiation
This Phase 3 study tests whether immunotherapy or targeted medicine, with or without a one-time focused brain radiation procedure, can control brain metastases from melanoma or non-small cell lung cancer. It mainly enrolls people who have no (or minimal) brain symptoms and are newly diagnosed in the brain (except for certain recent brain surgery).
NaplesAges 18 years+ - NCT05524584RecruitingPhase 2
Anastrozole, fulvestrant, and abemaciclib for hormone-positive breast cancer
This trial tests whether combining three medicines can better control hormone-receptor–positive, HER2-negative metastatic breast cancer that cannot be cured with surgery or radiation. It may help shrink tumors and slow disease growth compared with standard hormone therapy approaches.
Orange, CaliforniaAges 18 years+ - NCT05525338RecruitingPhase 4
Test standard vs adjusted alectinib dose using blood levels
This trial compares the usual dose of alectinib with a modified dose chosen by checking alectinib blood levels. It aims to see whether adjusting the dose based on blood testing can work as well (and possibly be better tolerated) for people with ALK-positive non-small cell lung cancer.
Villejuif, Val-de-MarneAges 18 years+ - NCT05537922Recruiting
Study uses data to tailor lung cancer care with immunotherapy
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
Chicago, IllinoisAges 18 years+ - NCT05559645Recruiting
Oral drug trial for EGFR-mutated lung cancer after prior treatment
This trial studies an oral (by mouth) EGFR-blocking medicine (DZD9008) in people with advanced lung cancer that has EGFR mutations. It’s for cancers that have grown despite standard treatment or couldn’t be tolerated, and aims to control the cancer while keeping side effects manageable.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05570825RecruitingPhase 2
Study drug SX-682 with pembrolizumab for advanced lung cancer
This trial tests SX-682 plus pembrolizumab (an immunotherapy) to treat metastatic or recurrent non-small cell lung cancer (NSCLC). It aims to see how well the combination works and whether it can shrink or control the cancer in people whose tumors have enough PD-L1.
Seattle, WashingtonAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study drug for advanced ovarian and other solid cancers
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Phoenix, ArizonaAges 18 years+ - NCT05589818RecruitingPhase 2
Pembrolizumab for advanced lung cancer without key gene targets
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
New York, New YorkAges 18 years+ - NCT05627960RecruitingPhase 1
Testing an antibody drug for advanced solid cancers
This Phase 1 study tests AG01, an antibody that targets a cancer protein called GP88, in people with advanced solid tumors. The goal is to find safe doses and learn whether it can help certain cancers.
Baltimore, MarylandAges 18 years+ - NCT05631249RecruitingPhase 2
Sotorasib for KRAS G12C lung cancer after prior treatments
This Phase 2 trial studies sotorasib, a targeted medicine, in people with non-small cell lung cancer (NSCLC) that has a specific KRAS mutation called G12C. You may be eligible if your cancer has spread or can’t be removed by surgery and has grown again after at least one previous treatment.
LyonAges 18 years+ - NCT05654454RecruitingPhase 3
Bevacizumab plus chemotherapy vs Avastin for advanced lung cancer
This trial compares a combination of anti-angiogenics (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) against Avastin-based treatment in people with advanced non-small cell lung cancer. It aims to find out whether the study treatment is safer and works better for shrinking tumors and improving outcomes.
ArkhangelskAges 18 years+ - NCT05657873RecruitingPhase 2
Targeted radiation for metastatic lung cancer with liver spread
This trial studies whether adding targeted radiation to the liver (small-area, high-precision radiation) can help people with stage IV non-small cell lung cancer. Participants also start standard “anti–PD-1/PD-L1” immunotherapy (with chemotherapy in some cases).
Miami, FloridaAges 18 years+ - NCT05671887Recruiting
Double lung transplant registry for certain lung-limited cancers
This study follows people who are getting a double lung transplant and have specific lung-only (or lung-limited) cancer or other serious lung conditions. It’s an observational registry, meaning it collects real-world information to learn which patients may benefit from transplant and how they do afterward.
Chicago, IllinoisAges 18–75 - NCT05681780RecruitingPhase 1
CD40L-treated immune cells for advanced lung cancer with certain gene changes
This Phase 1 study tests a lab-made immune cell treatment (TIL) boosted with CD40L, plus nivolumab, for stage IV or returning non-small cell lung cancer with specific gene changes (EGFR, ALK, ROS1, or HER2). It aims to help your immune system attack the cancer after it has grown despite standard treatments.
Tampa, FloridaAges 18 years+ - NCT05724004Recruiting
Alectinib then targeted radiation for ALK-positive lung cancer
This trial tests giving alectinib first, then adding targeted radiation to remaining spots of cancer in people with ALK-rearranged advanced non-small cell lung cancer. It aims to control the cancer after an initial response and help keep disease from progressing.
StockholmAges 20 years+ - NCT05733000RecruitingPhase 2
CPI-613 plus hydroxychloroquine with chemo for advanced solid tumors
This trial tests a drug called CPI-613 (devimistat) combined with hydroxychloroquine along with either 5-fluorouracil or gemcitabine chemo. It’s for people with advanced cancers that have stopped responding to standard treatments, aiming to shrink tumors and slow cancer growth.
Chicago, IllinoisAges 18 years+ - NCT05751798RecruitingPhase 1/Phase 2
Test drug OSE-279 for advanced lung cancer that has no key mutations
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
AnderlechtAges 18 years+ - NCT05752552RecruitingPhase 1
Safety study of a MET-targeting pill for advanced lung cancer
This Phase 1 trial tests DO-2 to see how safe it is and how the body absorbs it (pharmacokinetics) in people with advanced or metastatic lung cancer. It is for tumors that have a specific MET exon 14 “skipping” mutation and for whom standard treatments are no longer an option.
BrusselsAges 18 years+
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non small cell lung cancer metastatic?
- Yes. Clin2 currently lists 772 recruiting non small cell lung cancer metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non small cell lung cancer metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non small cell lung cancer metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Squamous Cell Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.